Aurobindo Pharma’s arm signs deal to set up JV in China

31 Aug 2019

Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare S.V, Netherlands, has entered into an agreement on August 29, 2019 with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co  for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Related Aurobindo Pharma Ltd. Links:

Aurobindo Pharma Share Price

432.55 -15.40 (-3.44%) Dec 10, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 427.50
Lupin 752.15
Dr. Reddys Lab 2896.95
Piramal Enterprises 1609.85
Cadila Healthcare 260.95
View more..
Sensex vs Aurobindo Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback

8055769463

8055769463